Literature DB >> 2193105

Phenylethylamine in the CNS: effects of monoamine oxidase inhibiting drugs, deuterium substitution and lesions and its role in the neuromodulation of catecholaminergic neurotransmission.

A A Boulton1, A V Juorio, I A Paterson.   

Abstract

Phenylethylamine is present in brain in tiny quantities, it is heterogeneously distributed and present in synaptosomes, and it is synthesized and degraded very quickly. If deuterium is substituted for hydrogen on the alpha carbon of the side chain then it exhibits profound isotope effects to MAO and its penetration and persistence in the brain is considerably enhanced. In the presence of MAO-B inhibitors treatment with reserpine causes reciprocal changes to PE and DA suggesting a functional relationship between them and after unilateral lesions of the substantia nigra an ipsilateral reduction in striatal PE is seen suggesting again a co-relationship with DA. Following iontophoresis PE has been shown to exhibit indirect sympathomimetic effects but in addition when applied at low currents concurrently with DA or NA it causes post synaptically a substantial potentiation in the actions of the latter amines. As a result of this and other data PE has been proposed to be a neuromodulator of catecholaminergic transmission.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2193105     DOI: 10.1007/978-3-7091-9050-0_12

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  8 in total

Review 1.  Monoamine oxidases in development.

Authors:  Chi Chiu Wang; Ellen Billett; Astrid Borchert; Hartmut Kuhn; Christoph Ufer
Journal:  Cell Mol Life Sci       Date:  2012-07-11       Impact factor: 9.261

2.  Decreased beta-phenylethylamine in CSF in Parkinson's disease.

Authors:  G Zhou; H Shoji; S Yamada; T Matsuishi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-12       Impact factor: 10.154

3.  Metabolism of 2-phenylethylamine and phenylacetaldehyde by precision-cut guinea pig fresh liver slices.

Authors:  Georgios I Panoutsopoulos; Demetrios Kouretas; Elias G Gounaris; Christine Beedham
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2004 Apr-Jun       Impact factor: 2.441

Review 4.  Trace amine-associated receptor 1-Family archetype or iconoclast?

Authors:  David K Grandy
Journal:  Pharmacol Ther       Date:  2007-07-17       Impact factor: 12.310

5.  Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson's Disease with Neuroprotective Potential.

Authors:  John P M Finberg
Journal:  Rambam Maimonides Med J       Date:  2010-07-02

6.  Anatomical and functional evidence for trace amines as unique modulators of locomotor function in the mammalian spinal cord.

Authors:  Elizabeth A Gozal; Brannan E O'Neill; Michael A Sawchuk; Hong Zhu; Mallika Halder; Ching-Chieh Chou; Shawn Hochman
Journal:  Front Neural Circuits       Date:  2014-11-07       Impact factor: 3.492

7.  A phase 1 trial of pharmacologic interactions between transdermal selegiline and a 4-hour cocaine infusion.

Authors:  Debra S Harris; Thomas Everhart; Peyton Jacob; Emil Lin; John E Mendelson; Reese T Jones
Journal:  BMC Clin Pharmacol       Date:  2009-08-01

8.  Plasma Biomarkers for Monitoring Brain Pathophysiology in FMR1 Premutation Carriers.

Authors:  Cecilia Giulivi; Eleonora Napoli; Flora Tassone; Julian Halmai; Randi Hagerman
Journal:  Front Mol Neurosci       Date:  2016-08-12       Impact factor: 5.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.